UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 14.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 304,755 shares of the medical research company's stock after acquiring an additional 38,774 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.20% of Bruker worth $21,046,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. lifted its holdings in shares of Bruker by 120.4% during the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company's stock worth $25,000 after purchasing an additional 218 shares during the period. UMB Bank n.a. grew its position in shares of Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock valued at $46,000 after buying an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker in the second quarter valued at about $52,000. GAMMA Investing LLC raised its position in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock worth $60,000 after acquiring an additional 388 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Bruker by 20.0% in the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company's stock worth $63,000 after acquiring an additional 165 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.
Bruker Stock Performance
Shares of NASDAQ BRKR traded up $0.48 during mid-day trading on Friday, reaching $58.96. 1,094,026 shares of the company's stock were exchanged, compared to its average volume of 1,114,777. The firm has a market capitalization of $8.94 billion, a price-to-earnings ratio of 28.35, a price-to-earnings-growth ratio of 3.86 and a beta of 1.18. The firm has a 50-day moving average price of $59.61 and a two-hundred day moving average price of $63.48. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker Co. has a 52 week low of $48.07 and a 52 week high of $94.86.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to analysts' expectations of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company's revenue was up 16.4% compared to the same quarter last year. During the same period last year, the business posted $0.74 EPS. Analysts predict that Bruker Co. will post 2.4 EPS for the current year.
Bruker Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a yield of 0.34%. Bruker's dividend payout ratio is currently 9.62%.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on BRKR. Barclays dropped their target price on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. TD Cowen reduced their target price on Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their target price on Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Citigroup reduced their price objective on Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective for the company in a report on Thursday. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bruker has an average rating of "Moderate Buy" and an average target price of $79.36.
Get Our Latest Research Report on Bruker
Insiders Place Their Bets
In related news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 28.30% of the company's stock.
Bruker Company Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
![Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&Symbol=BRKR)
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.